Rapid Information on OLM No 213 140331Rapid Information on OLM No 213 140331.doc

Rapid Information on Olmesartan and other ARBs No.213 2014/03/31 　　　　　　　　　　　　　　　　　 　　　　　　　　　Be the first to know! 　　　 　 　　 (Toru Komai, Ph.D.) 213-1: Olmesartan might be a new upstream arrhythmia therapy by modulating intercellular junctions remodeling through β-catenin signaling pathway. Title：Rapid electrical stimulation causes alterations in cardiac intercellular junction proteins of cardiomyocytes 2-3 213-2: Patients with primary hypertension have decreased ghrelin level in peripheral blood, which increases significantly after BP control with valsartan. Title：Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension 3-4 Following three are the abstract of papers presented at the annual scientific meeting of Japanese Circulation Society in March 21~23, 2014, in Tokyo. 213-3: Effect of Long-Term Administration of Olmesartan and Azelnidipine Combination Therapy Compared to Olmesartan Monotherapy on Insulin Resistance in Hypertension 5 213-4: Effects of Olmesartan-based Versus Amlodipine-based Treatments on Serum and Urine Marker Modification in Essential Hypertension 6 213-5: Effects of Olmesartan on ACE2/Ang-(1-7)/Mas Receptor Axis and EPC in the Kidney of Spontaneously Hypertensive Rats 7 Abbreviations: BP: blood pressure, SBP/DBP: systolic/ diastolic BP, RAS: renin–angiotensin system, Ang II: angiotensin II, ARB: angiotensin II receptor blocker, 213-1: Olmesartan might be a new upstream arrhythmia therapy by modulating intercellular junctions remodeling through β-catenin signaling pathway. Cardiomyocytes are connected with each other through intercellular junctions, which contain two complexes, adhesion junction (AJ) and gap junction (GJ). GJs provide the pathway for interc